Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 9
2004 6
2005 11
2006 10
2007 6
2008 5
2009 8
2010 3
2011 6
2012 3
2013 5
2014 10
2015 9
2016 10
2017 5
2018 7
2019 9
2020 3
2021 7
2022 12
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Ferrari MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, Murugan P, Hahm E, Yu J, Kuzel TM, Gradilone SA, Mansini AP. Ferrari MG, et al. Among authors: kuzel tm. Oncogene. 2024 Feb;43(7):484-494. doi: 10.1038/s41388-023-02925-x. Epub 2023 Dec 23. Oncogene. 2024. PMID: 38135694 Free PMC article.
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.
Carthon BC, Kim SE, McDermott DF, Dutcher JP, Puligandla M, Manola J, Pins M, Carducci MA, Plimack ER, Appleman LJ, MacVicar GR, Kohli M, Kuzel TM, DiPaola RS, Haas NB. Carthon BC, et al. Among authors: kuzel tm. Clin Genitourin Cancer. 2023 Oct;21(5):546-554. doi: 10.1016/j.clgc.2023.06.012. Epub 2023 Jul 3. Clin Genitourin Cancer. 2023. PMID: 37455214 Clinical Trial.
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR, Wang SJ, Thandoni A, Bommareddy PK, Newman JH, Marzo AL, Kuzel TM, Gupta V, Reiser J, Daniels P, Schiff D, Mitchell D, LeBoeuf NR, Simmons C, Goyal S, Lasfar A, Guevara-Patino JA, Haffty BG, Kaufman HL, Silk AW, Zloza A, Giurini EF. Jhawar SR, et al. Among authors: kuzel tm. J Immunother Cancer. 2023 Jul;11(7):e006780. doi: 10.1136/jitc-2023-006780. J Immunother Cancer. 2023. PMID: 37433716 Free PMC article.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Coveler AL, Smith DC, Phillips T, Curti BD, Goel S, Mehta AN, Kuzel TM, Markovic SN, Rixe O, Bajor DL, Gajewski TF, Gutierrez M, Lee HJ, Gopal AK, Caimi P, Heath EI, Thompson JA, Ansari S, Jacquemont C, Topletz-Erickson A, Zhou P, Schmitt MW, Grilley-Olson JE. Coveler AL, et al. Among authors: kuzel tm. J Immunother Cancer. 2023 Jun;11(6):e005584. doi: 10.1136/jitc-2022-005584. J Immunother Cancer. 2023. PMID: 37385724 Free PMC article. Clinical Trial.
Minimum thresholds deemed acceptable by patients and physicians for sensitivity and specificity of mobile skin cancer screening algorithms.
Anvery N, Kang B, Christensen RE, Dirr MA, Nadir U, Brieva JC, Council ML, Dover JS, Kuzel TM, Minkis K, Mittal BB, Wayne JD, Yoo SS, Alam M. Anvery N, et al. Among authors: kuzel tm. J Am Acad Dermatol. 2023 Sep;89(3):595-597. doi: 10.1016/j.jaad.2023.05.019. Epub 2023 May 13. J Am Acad Dermatol. 2023. PMID: 37187429 No abstract available.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. Choueiri TK, et al. Among authors: kuzel tm. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. J Immunother Cancer. 2022. PMID: 36328377 Free PMC article. Clinical Trial.
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Kim EJ, et al. Among authors: kuzel tm. JAMA Dermatol. 2022 Sep 1;158(9):1031-1039. doi: 10.1001/jamadermatol.2022.2749. JAMA Dermatol. 2022. PMID: 35857290 Free PMC article. Clinical Trial.
Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas.
Khaliq AM, Erdogan C, Kurt Z, Turgut SS, Grunvald MW, Rand T, Khare S, Borgia JA, Hayden DM, Pappas SG, Govekar HR, Kam AE, Reiser J, Turaga K, Radovich M, Zang Y, Qiu Y, Liu Y, Fishel ML, Turk A, Gupta V, Al-Sabti R, Subramanian J, Kuzel TM, Sadanandam A, Waldron L, Hussain A, Saleem M, El-Rayes B, Salahudeen AA, Masood A. Khaliq AM, et al. Among authors: kuzel tm. Genome Biol. 2022 Jul 13;23(1):156. doi: 10.1186/s13059-022-02724-9. Genome Biol. 2022. PMID: 35831907 Free PMC article. No abstract available.
139 results